Provider review · Public documents checked September 27, 2026
NIOD CAIS3 copper-peptide serum review: two peptides, two sizes and distinct evidence limits
Read the 1:1 description, current ingredient declaration and manufacturer study footnotes without converting them into a clinical ranking.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
A product name containing both a generation number and a ratio can invite a misleading shortcut. The number may identify a version, while the ratio refers to two different named components. Neither tells a reader how the whole formula compares with a cream or whether it has been tested against the alternatives they are considering.
This review examines NIOD’s current CAIS3 manufacturer record and separately verified size prices. It is written for Facework, a publication within CoreAge Rx’s promotional network, where CoreAge has first commercial placement. We have not performed a clinical review, analyzed a bottle or tested NIOD against the sponsor’s product.
In this article
CAIS3 is the serum, not the similarly named lipid product
The manufacturer page identifies Copper Amino Isolate Serum 3 1:1 as a water-based serum. NIOD also markets Copper Amino Isolate Lipid, a different product. Product cards for that alternative appear nearby, but its price, ingredients and texture should not be assigned to CAIS3.
The current CAIS offer displays $62 for 15 mL. A fresh public size-selection response confirms $93 for 30 mL. This review did not add either to a cart or test shipping. The shortlist keeps those sizes attached to the figures, because a default page price is not evidence that every available bottle costs the same.
The ratio names different peptide components
NIOD describes 1% GHK-Cu alongside 1% GHK. The copper-containing complex and the separately named peptide are not presented as two identical copper-peptide portions. Calling the formula 2% copper peptide would therefore lose the distinction the manufacturer makes, even though both numbers appear in the same explanation.
The percentage guide compares that wording with CoreAge's advertised 2% and The Ordinary's 1% title. It does not calculate equivalent strength across the products. We have no independent assay, shared analytical method or head-to-head delivery study that could support such a conversion. A more detailed manufacturer description can improve identification without proving that its formula delivers the strongest result.
The declaration supplies a broader formula picture
The current ingredient list begins with water and glycerin and includes Tripeptide-29, Tripeptide-1 Copper Acetate, Tripeptide-1 Acetate and additional peptide ingredients. Hyaluronate crosspolymer, glycogen and several formulation aids also appear. This is a multi-ingredient product, not a clinical test of GHK-Cu in isolation.
NIOD warns that its formulas are updated and the online list can differ from packaging by purchase time and region. The package-question guide explains why a supplied box remains relevant. This review reports the current declared names without claiming to have verified their concentrations or reconciled every chemical naming convention through laboratory analysis.
The study footnotes describe small product evaluations
The page attributes four- and eight-week appearance claims to testing on 31 people and a twelve-week claim to testing on 32 people. These are manufacturer summaries for the product. They are more specific than an unexplained science badge, but they do not provide this review with full participant characteristics, comparator details, allocation methods or complete results for independent appraisal.
We therefore do not combine the groups into a larger trial, assume independent replication or treat the summary as a published comparison against another brand. The page mixes language about skin feeling smoother with language about visible wrinkles. Those outcomes may require different assessments; a shared clinical-testing label does not make every claim the same measurement.
A product evaluation is not transferable aftercare evidence
The older copper-tripeptide study abstract addressed skin after carbon-dioxide laser resurfacing, not this ordinary serum offer. Thirteen completers showed no significant between-group objective advantage in redness, wrinkles or overall skin quality, although questionnaire satisfaction favored the GHK-Cu regimen. It cannot be turned into proof of CAIS3 aftercare benefits or a conclusion about all daily cosmetic use.
The procedure guide keeps that distinction visible. Skin that has recently undergone treatment is not simply another setting for a general healthy-looking-skin claim. This publication supplies no post-procedure regimen, wound-care instruction or assurance that a serum's cosmetic description makes it appropriate for freshly treated skin.
Format and regulatory context still matter
NIOD's water-based serum is not a face cream merely because its claims overlap with cream advertising. The moisturizer guide considers what the complete base may contribute. AAD guidance discusses dryness and suitable moisturization around menopause, but it does not demonstrate that this serum replaces a moisturizer for every person or outperforms other formats.
FDA's cosmetics explanation also distinguishes cosmetic marketing from approved-drug review. A product can carry cosmetic appearance claims without having FDA preapproval, while its seller remains responsible for safety and labeling. That does not give Facework a legal compliance verdict or a tolerance guarantee; it explains why familiar clinical-sounding language needs careful interpretation.
What the comparison leaves open
The CoreAge review addresses a compounded offer with a percentage-specification gap and cream-versus-serum wording conflict. The Ordinary review addresses another multi-peptide serum with its own declaration and compatibility guidance. These are actual differences in the information offered, not evidence that one treatment is universally superior.
For CAIS3, the remaining questions concern the exact supplied version, the complete meaning of the study summaries and how the product fits a person's existing care. We have not tested those matters. The fair conclusion is a clearly identified serum with explicit manufacturer peptide descriptions and small product-study claims, whose strength comparison, personal effects and relative clinical benefit remain unverified here.
Sources behind this reading
- NIOD: Copper Amino Isolate Serum 3 1:1, US page ↗Manufacturer product and study summaries; direct public size response verifies 30 mL price · Checked 2026-09-27
- Effects of Topical Copper Tripeptide Complex on CO2 Laser-Resurfaced Skin ↗Primary clinical-study abstract; 13 completers in procedure-specific setting; full report not reviewed · Checked 2026-09-27
- American Academy of Dermatology: Caring for Your Skin in Menopause ↗Professional patient education; general skin-care context, not product testing · Checked 2026-09-27
- FDA: Cosmetics and US Law ↗Regulator explanation of cosmetic/drug and approval distinctions · Checked 2026-09-27